Molecular mechanism of action and safety of 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione – a novel anticonvulsant drug candidate

Barbara Kapronś1, Jarogniew Łuszczyk2, Agata Paneth1, Monika Wujec3, Agata Siwek4, Tadeusz Karcz5, Barbara Mordy4, Monika Głuch-Lutwin4, Anna Gryboś5, Gabriel Nowak4, Karolina Pająk6, Krzysztof Jóźwiak6, Adam Tomczykowski1, Tomasz Plech2

Abstract

Previously, it was found that 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (TP-315) effectively protects mice from maximal electroshock-induced seizures. The aim of this study was to determine possible interactions between TP-315 and different molecular targets, i.e. GABAα receptors, voltage-gated sodium channels, and human neuronal α7 and α4β2 nicotinic acetylcholine receptors. The influence of TP-315 on the viability of human hepatic HepG2 cells was also established using PrestoBlue and ToxiLight assays. It was found that the anticonvulsant activity of TP-315 results (at least partially) from its influence on voltage-gated sodium channels (VGSCs). Moreover, the title compound slightly affected the viability of human hepatic cells.

Key words: Sodium channels; [3H]-batrachotoxin; patch-clamp; cell viability assays.

Introduction

Epilepsy is a neurological disorder in which abnormal excessive and/or hypersynchronous neuronal activity occurs causing seizures or other symptoms, like temporary confusion, loss of consciousness or awareness, unusual sensations, etc. The main aim of treatment of epilepsy is to obtain a seizure-free state or to reduce seizure frequency in patients. The main form of treatment of epilepsy in humans is the administration of anti-epileptic drugs (AEDs). However, about one-third of patients with epilepsy suffer from seizures that cannot be fully controlled with currently available AEDs [1, 2]. Simultaneously, it is well known that dose-dependent and reversible adverse effects of AEDs are common, especially in patients treated with polytherapy [3]. Therefore, there is an immense demand for the development of novel anticonvulsant drugs, especially such ones that offer better tolerability with limited adverse effects.

Recently, the screening tests performed in our laboratory revealed that 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (TP-315; Fig. 1) produced evident anticonvulsant action in the maximal electroshock-induced seizure model in mice (Fig. 2) [4]. Moreover, the triazole derivative TP-315 appeared to have a beneficial protective index.

However, until now nothing was known about the mechanism(s) involved in the anticonvulsant activity of TP-315. Molecular target identification is one of the most important steps in developing drug
candidates [5]. Nonetheless, even such molecules that strongly interact with their biological target(s) can fail to become successful drug because of safety concerns. So, it is important to evaluate the potential toxicity in early stages of drug development. The aim of the present study was to examine the effect of TP-315 on different molecular targets in the central nervous system, i.e. GABA$_A$ receptors, voltage-gated sodium channels, and human neuronal $\alpha7$ and $\alpha4\beta2$ nicotinic acetylcholine receptors. Moreover, the cellular toxicity of TP-315 towards human hepatic cells was investigated using two types of viability measuring assays, i.e. PrestoBlue and ToxiLight assays.

![Chemical structure of TP-315](image)

**Figure 1.** Chemical structure of TP-315

**Figure 2.** Time-course and dose-response effects of TP-315 in the maximal electroshock-induced seizure (MES) and chimney tests in mice. Left panel: Dose-response function for the anticonvulsant (protective) activity (A) and acute neurotoxic impairment of motor coordination (B) of TP-315 in the MES and chimney tests. Each data point (n=8 mice/data point) represents percent of mice protected from the MES test (A), or percent of mice with impairment of motor coordination in the chimney test (B), at a given dose (in mg/kg) of TP-315 in various pretreatment times (15, 30, 60 and 120 min). Sigmoidal curves are the result of a least squares fit of dose-response function for the tested compound (TP-315). Points of intersections with the dashed line at 50% correspond to approximate $ED_{50}$ values (A) or $TD_{50}$ values (B) of TP-315. Right panel: Columns represent median effective doses ($ED_{50}$ in mg/kg ± S.E.M.) of TP-315 (A), that protect 50% of animals tested against MES-induced seizures in mice, or median toxic doses ($TD_{50}$ in mg/kg ± S.E.M.) of TP-315 (B), that impair motor coordination in 50% of the mice subjected to the chimney test. The log-probit method was used for calculating the $ED_{50}$ and $TD_{50}$ values of TP-315 at 4 various pretreatment times (15, 30, 60 and 120 min).
Experimental procedures

**GABA\(_A\) electrophysiology**

Electrophysiology experiments were carried out on a QPatch16X automatic patch clamp platform (Sophion Biosciences). HEK293 cells, stably expressing the α1β2γ2 subunits of the human GABA\(_A\) receptor were cultured using standard procedures. On the day of experiment cells were collected from the culture flask using Detachin solution (VWR) and resuspended in serum-free media. Cell suspension was placed in the magnetic stirred tube, located onboard the automated electrophysiology instrument and allowed to recover for 60 minutes at room temperature. In the next step, cells were automatically transferred to a built-in centrifuge, spun down and washed in extracellular Ringer’s solution. Cells were applied to the pipetting wells of a disposable 16-channel planar patch chip plates (QPlate 16X, with 10 patch clamp holes per measurement site) and gigaseals were formed upon execution of a combined suction/voltage protocol. Further suction lead to whole-cell configuration. GABA\(_A\) receptor chloride currents were recorded for 7s after each addition of compound. During whole-cell recording, the holding potential was set to -90 mV. Recordings were performed at room temperature. Extracellular solution consisted of (in mM): 2 CaCl\(_2\), 1 MgCl\(_2\), 10 HEPES, 4KCl, 145 NaCl, 10 glucose (pH 7.4, 300 mOsm) and intracellular solution contained (in mM): 140 CsF, 1 EGTA, 5 CsOH, 10 HEPES, 20 NaCl (pH 7.2, 320 mOsm).

In the agonist assays, the sequential application of: 10 μM γ-aminobutyric acid (GABA, reference agonist at concentration close to half maximal effective concentration); 10 μM tested compound (TP-315) and second addition of 10 μM GABA was set up in the instrument software. The interval between additions of particular compounds was at least 60s. Typically 5 μl of ligand was added to the cells, which was followed after 3s by washout with extracellular solution (two times 5 μl).

In the allosteric modulator/antagonist dose-response mode (simultaneous addition of GABA and tested compound) first 10 μM GABA application was followed by 6 additions of increasing concentrations of tested compound (0.001-100 μM) in combination with 10 μM GABA. In this setup, cells were preincubated with potential allosteric modulator/antagonist alone for at least 50 s, before the addition of combination with agonist. Concentration of reference agonist used in this study (being close to EC\(_{50}\) value) was chosen during method validation process and enabled the detection of both antagonist (e.g. bicuculline) and positive allosteric modulator (e.g. zolpidem) activity in single setup [6].

Data were analyzed using QPatch Assay Software (v5.0, Sophion Biosciences) and represented the mean of at least three experiments carried out on distinct cells. Validation criteria for each experiment were: current amplitude evoked by addition of GABA higher than 500 pA and difference between cells response to both GABA applications in agonist mode not higher than 25%.

**Radioligand binding assay for Na\(^+\) channel - site 2 using \[^{3}H\]batrachotoxin**

Radioligand assay was performed according to the method of Callaway et al. [7] with slight modifications. Rat cerebral cortex was weighed and homogenised at concentration of 10% (w/v) in ice-cold 0.32 M sucrose, 10 mM phosphate buffer (pH 7.4) using an ULTRA TURRAX homogeniser. The homogenate was centrifuged at 1000 x g for 10 min (0-4°C). Collected supernatant was centrifuged at 40 000 x g for 45 min (0-4°C) to obtain membrane fraction. The resulting pellet was resuspended in incubation buffer containing (mM): 50 Tris base, 50 HEPES, 130 choline chloride, 5.4 KCl, 0.8 MgSO\(_4\) and 5.5 glucose (pH 7.4). 300 μl of the tissue suspension (300 μg/well) containing LQ scorpion venom (10 μg/well), 50 μl of \[^{3}H\]BTX solution (final conc. 10 nM, spec. act. 38.6 Ci/mmol, PerkinElmer) and 50 μl of the tested compounds were incubated at 37°C for 1 h. The incubation was terminated by rapid filtration over glass fiber filters (FilterMate B, PerkinElmer) using 96-well harvester (PerkinElmer). Eight rapid washes with 500 μl of ice-cold 50 mM Tris-HCl buffer, pH 7.4, were performed. Veratridine (300 μM) was used to define nonspecific binding.

Filter mates were dried at 37°C in forced-air incubator and solid scintillator (MeltiLex, PerkinElmer) was then melted on them at 100°C for 5 minutes. The radioactivity on the filters was measured in MicroBetaTriLux 1450 scintillation counter (PerkinElmer). Each compound was tested in a screening assay at final concentration of 100 μM. Results were expressed as percent inhibition of \[^{3}H\]batrachotoxin binding. Then compound TP-315, qualified for dose-response binding experiments, was tested in 8 concentrations ranging from 300 to 0.1 μM.

**Interaction of TP-315 with orthosteric sites of human α7 and human α4β2 nicotinic acetylcholine receptors (nAChRs)**

**Reagents**

See Table A.
**Table A. Reagents**

|                           | Supplier                        |
|---------------------------|---------------------------------|
| [3H]Epibatidine (62.2 Ci/mmol) | Perkin Elmer                    |
| (±)-Epibatidine dihydrochloride hydrate | Sigma-Aldrich            |
| Polyethylenimine (PEI)      | Protease inhibitors cocktail     |
| Sodium azide (NaN3)         | Trizma base                     |
| Trizma hydrochloride        | Sodium chloride (NaCl)          |
| Potassium chloride (KCl)    | Di-sodium hydrogen phosphate (NaH2PO4) |
| Sodium chloride (NaCl)      | Postassium phosphate monobasic (KH2PO4) |
| CaCl2                      | CaCl2                            |
| MgCl2                      | Fetal bovine serum (FBS)         |
| Trypsin/EDTA               | Dulbecco’s Modified Eagle Medium (DMEM) |
| Ham’s F-12 nutrient mixture | Hygromycin B                    |
| Genetecin (G-418 sulfate)   | Life Technologies               |

**Membrane preparation**

nAChRs binding experiments were performed on membranes from HEK-293 and SHSY5Y cells stably transfected with genes encoding hα4β2 and hα7 nAChRs, respectively. Method of Arias et al. was used to obtain membranes and perform binding assay [8].

HEK293-hα4β2 cells were maintained in 1:1 mixture of Dulbecco’s Modified Eagle Medium (DMEM) and Ham’s F-12 nutrient mixture supplemented with 10% fetal bovine serum (FBS), 200 µg/ml G-418 and 200 µg/ml hygromycin B. SHSY5Y-hα7 were cultured in DMEM supplemented with 10% FBS and 200 µg/ml G-418. Cells were cultured for approximately 3 weeks in suspension on nontreated Petri dishes, then gently scraped and centrifuged at 500 x g for 5 min. Cells were then homogenized in binding saline buffer (50 mM Tris-HCl, pH 7.4 containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2) supplemented with a cocktail of protease inhibitors and 0.025% sodium azide and centrifuged at 10,000 rpm for 30 min at 4°C. The pellet was finally resuspended in binding saline buffer containing 20% sucrose. Aliquots of AChR membranes were stored at -80°C.

**Radioligand binding assay**

Radioligand binding assay was performed in 96-well plate format. AChR membranes (1 mg/ml), were suspended in binding saline buffer containing 10 nM [3H]Epibatidine and preincubated for 10 min at room temperature following the addition of TP-315. Nonspecific binding was determined in the presence of 1 µM (±)-epibatidine. After 90 min incubation at room temperature, the AChR-bound radioligand was separated from the free [3H]epibatidine by a filtration assay using a 96-sample harvester system with GF/B Whatman filters, previously soaked with 0.5% polyethylenimine for 30 min. The bound radioactivity was determined using the MicroBetaTriLux scintillation counter (Perkin Elmer).

**Cell viability and cytotoxicity assays**

**Cell culture**

The human hepatocellular carcinoma cells (HepG2) were obtained from the ATCC (HB-8065). The cells were thawing according to the manufacturer’s protocol form ATCC. HepG2 cells are cultivated in Eagle’s Minimum Essential Medium (EMEM, ATCC) supplemented with 10% heat inactivated fetal bovine serum (ATCC), with added 100 IU/ml penicillin (ATCC) and 100 µg/ml streptomycin (ATCC). The cells were passaged three times a week, until they reached confluence. HepG2 cells culture were carried out in accordance with basic techniques of cell culture in sterile conditions. Cells were cultured in flasks with an area of 175 cm², and incubated at 37°C, 5% CO2. For the test of compounds with the HepG2 cells line, hepatocytes were seeded on 96-well culture plate at a density of 2x10⁴ cells per well in fresh medium. Cells grew for 24 hours in the incubator (37°C, 5% CO2) before performing experiments.

**Sample preparation**

TP-315 was dissolved in dimethyl sulfoxide (DMSO) with stock concentrations of 10 mM. The compounds were incubated for 5 minutes with ultrasound in a water bath. From the stock, dilutions were prepared in phosphate buffered saline (PBS). All experiments were performed in triplicates, in two independent experiments.

**PrestoBlue assay**

Cell viability was measured using the PrestoBlue reagent (Invitrogen). PrestoBlue reagent is a resazurin-based solution that functions as a cell viability indicator. Metabolically active cells are capable of reducing the PrestoBlue reagent, with the colorimetric changes used as an indicator to quantify the viability of cells in culture. This change can be determined by measuring the fluorescence. After 24 hours of incubation with the compounds the PrestoBlue reagent was added to wells of a microplate in an amount equals to one tenth of the remaining medium volume. After 15 minutes of incubation at 37°C, the fluorescence intensity (EX 530 EM 580 nm)
was measured in a plate reader (POLARstar Omega, BMG Labtech). Viability values were calculated as a percentage of live cells with respect to the control sample (DMSO). The negative control was medium without cells.

**ToxiLight assay**

The bioluminescent ToxiLight bioassay (Lonza) is a cytotoxicity highly sensitive assay designed to measure cell membrane damage. It quantitatively measures the release of Adenylate Kinase (AK) from the membranes of damaged cells. AK is a protein presented in all eukaryotic cells, which is released into the culture medium when cells die. The enzyme actively phosphorylates ADP and the resultant ATP is then measured using the bioluminescent firefly luciferase reaction with the ToxiLight reagent. The emitted light intensity expressed as a RLU value is linearly related to the adenylate kinase activity. After 24 h of treatments, 5 μl of the clear fluid above sediment was transferred into 384-well plate (Perkin Elmer). Then 20 μl of the Adenylate Kinase Detection Reagent (AKDR) was added. As a positive control for lysis 10% Triton X-100 (Sigma-Aldrich) in growth medium is used, the negative control is growth medium alone. The luminescence was measured in a plate reader (POLARstar Omega, BMG Labtech) after 5 minutes of incubation. The results were expressed as a percentage of live cells with respect to the control sample.

**Results**

**Influence of 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (TP-315) on the GABA<sub>A</sub> receptor chloride currents**

5-(3-Chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (TP-315) in 10 μM concentration was not able to evoke GABA<sub>A</sub> receptor chloride current, when added directly to QPlate measurement site containing recombinant HEK-293 cells in whole-cell configuration (Fig. 3A). Thus, it can be stated that TP-315 lacks significant efficacy at GABA<sub>A</sub> receptors. Moreover, no potentiation, neither blockade of GABA-evoked currents was observed when GABA (10 μM) was used in combination with different concentrations of TP-315 (i.e. 0.001 μM - 100 μM) (Fig. 3B). Therefore, it can be concluded that TP-315 does not possess allosteric modulatory nor (ant)agonistic properties at GABA<sub>A</sub> receptors.

**Radioligand binding assay for Na<sup>+</sup> channel (site 2) using [3H]batrachotoxin**

Affinity of TP-315 to sodium channels – site 2 was expressed as a percentage of inhibition of the binding of [3H]batrachotoxin. Initially, TP-315 was tested in a screening assay at final concentration of 100 μM and it was found to be very effective sodium channel blocker with %inhibition amounted to 92 ± 4% (Table 1). Interestingly, carbamazepine, known as anti-epileptic drug acting on sodium channels, revealed much weaker inhibition of [3H]batrachotoxin binding (i.e. 17.4%). In the next step, radioligand binding assay was performed with varying concentrations of TP-315 in order to obtain dose-response curve (Fig. 4). Median inhibitory concentration (IC<sub>50</sub>) for TP-315 turned out to be 6.21 ± 0.80 μM whereas IC<sub>50</sub> for carbamazepine equalled 131 μM. The other two reference substances, veratridine and lidocaine, inhibited the binding of [3H]batrachotoxin to a receptor site of sodium channel with IC<sub>50</sub> of 16.7 ± 1.8 μM and 390 ± 126 μM, respectively.

**Interaction of TP-315 with orthosteric sites of human α7 and human α4β2 nicotinic acetylcholine receptors (nAChRs)**

Binding experiments were performed on membranes derived from HEK-293 and SH-SY5Y cells stably transfected with genes encoding human α4β2 and human α7 nicotinic acetylcholine receptors (nAChRs). TP-315 at 100 μM concentration does not displace [3H]epibatidine from its complexes neither with haα4β2 nor haβ7 nAChRs (Fig. 5).

| Compounds          | % inhibition ± SEM at 100 μM | IC<sub>50</sub> ± SEM [μM] |
|--------------------|------------------------------|----------------------------|
| TP-315             | 92 ± 4                       | 6.21 ± 0.80                |
| Veratridine        | 100 ± 2                     | 16.7 ± 1.8                 |
| Lidocaine          | 26 ± 2                      | 390 ± 126                  |
| Carbamazepine      | 17.4<sup>1</sup>             | 131<sup>2</sup>            |

Data represents the mean (± SEM) of two independent experiments, each conducted in duplicates.

<sup>1</sup>data obtained from [9]; <sup>2</sup>data obtained from [10]
Figure 3. Influence of TP-315 on GABA\textsubscript{A}-receptor mediated currents; A. current recordings for electrophysiological agonist-mode screening experiments; B. dose-dependent influence of TP-315 on GABA-gated chloride current in HEK-293 cells expressing recombinant GABA\textsubscript{A} receptor (TP-315 used in combination with 10 µM GABA).

**Influence of TP-315 on the viability of human HepG2 cells**

Human liver-derived cell lines are often used in drug development process for assessing safety of drug candidates. Toxicity of TP-315 was tested using immortalized hepatocellular carcinoma cells HepG2. The mentioned cell line constitutes one of the most frequently used model to study toxicity of drugs and chemicals [11-13]. In order to evaluate the viability of HepG2 cell after exposure to TP-315 PrestoBlue and ToxiLight assays were used. While PrestoBlue assay measures metabolic activity of cells (precisely, it measures cellular reducing activity), the ToxiLight assay was designed to measure cell membrane damage (i.e. it quantitatively measures the release of adenylate kinase from the membranes of damaged cells). The reference drug, astemizole, inhibited the viability of HepG2 cells in a dose-dependent manner. As its concentration increased from 1 µM to 100 µM the viability of cells decreased from 113% to 2% and from 93% to 14% in PrestoBlue and ToxiLight assays, respectively (Table 2). At the same experimental conditions TP-315 used in the highest concentration of 100 µM inhibited the growth of cells only by 6% (as measured in ToxiLight assay) and 15% (as measured in PrestoBlue assay).
**Figure 4.** Dose–response binding curves for TP-315, veratridine and lidocaine obtained in [3H]batrachotoxin binding assay for Na+ channels – site 2. Graphs from two independent experiments performed in duplicates with mean IC50 values ± SEM are shown.

![Graphs](image)

**IC50** values:
- TP-315: 6.21 ± 0.80 µM
- Veratridine: 16.7 ± 1.80 µM
- Lidocaine: 390 ± 126 µM

**Figure 5.** Displacement of [3H]epibatidine from its complexes with human α7 and human α4β2 nicotinic acetylcholine receptors (nAChRs).

![Graphs](image)

**Table 2.** Influence of different concentrations of TP-315 on the viability of human liver HepG2 cells using PrestoBlue and ToxiLight assays

| Type of assay | PrestoBlue          | ToxiLight        |
|---------------|---------------------|------------------|
|               | Viability (% of control) | Viability (% of control) |
| Concentration of compounds | 100µM | 50µM | 10µM | 1µM | 100µM | 50µM | 10µM | 1µM |
| TP-315        | 75% | 92% | 103% | 87% | 94% | 95% | 95% | 95% |
| Astemizole    | 2% | 20% | 68% | 113% | 14% | 20% | 85% | 93% |

**Discussion**

Molecular mechanisms of action of antiepileptic drugs (AEDs) are varied. Three main groups of mechanisms include: (i) modulation of ion channels (sodium, calcium, potassium), (ii) enhancement of GABA-ergic (inhibitory) neurotransmission, and (iii) diminishing of glutamatergic (excitatory) neurotransmission. In case of many AEDs, their activity is decided by more than one molecular mechanism. The chemical structure of TP-315, containing a five-membered 1,2,4-triazole ring, made it possible for the compound to have effect on GABAA receptors. When researching the antiepileptic effect of loreclezole Wingrove and co-workers proved that 1,2,4-triazole ring of loreclezole interact with the amide group of Asn-289, which is situated on the β2 subunit of the GABAA receptor [14]. Our previously conducted radioligand binding experiments with the use of radiolabeled ligands of GABAA receptor, i.e. [3H]muscimol and [3H]flunitrazepam, showed that 4,5-disubstituted 1,2,4-triazole-3-thione derivatives did not possess the affinity to their respective active sites [15, 16]. The mentioned lack of affinity concerned both aromatic and aliphatic derivatives of 1,2,4-triazole-3-thione. However, GABAA receptor complex contains many orthosteric and allosteric binding sites [17], and therefore, finding that there is no interaction between 4,5-disubstituted 1,2,4-triazole-3-thiones and muscimol- and benzodiazepine-binding sites does not exclude the possibility of other effects on GABAA receptor.

[Link to Medsci.org]
Therefore, in the course of searching for the mechanism of anticonvulsant activity of TP-315 we applied the patch clamp technique, that allows to investigate the influence of the compound on the chloride current through the GABA_A receptor. It has been determined, during the electrophysiological experiments, that TP-315 did not cause any changes in chloride ion current. Moreover, it neither intensifies nor inhibits GABA-evoked currents. Therefore, the obtained results justify the statement that TP-315 does not show the (anti)agonistic nor allosteric effect on GABA_A receptor.

The anticonvulsant activity of TP-315 was identified in the mouse maximal electroshock-induced seizure (MES) test, which is an experimental model of human generalized tonic-clonic seizures [18]. The MES-induced seizure test still remains one of the basic screening models used for the identification of new compounds showing anticonvulsant effects [19]. Numerous researches have proven that the anticonvulsant activity observed in the MES-induced seizure test is a result of interaction between the tested compound and voltage-gated sodium channels (VGSCs) [20]. In spite of such premises, the results presented herein provide the first experimental proof that TP-315 shows strong affinity towards the VGSCs. TP-315 displaced [3H]batrachotoxin from its binding site much stronger than veratridine and lidocaine. Moreover, TP-315 turned out to possess stronger affinity towards sodium channels than carbamazepine, the first generation AED acting on VGSCs.

Sodium channels blockers, i.e., compounds disturbing the conduction of sodium ions through sodium channels, serve as local anaesthetics as well as antiarrhythmic and antiepileptic drugs. The quite new application of sodium channel blockers results from the fact that they are thought to inhibit excitotoxic damage of neurons [7]. Therefore they may show neuroprotective effects [21, 22]. Certainly, the hypothesis assuming that TP-315, beside the anticonvulsant activity, also shows neuroprotective effects shall require confirmation in experimental conditions. Nevertheless, in case of other AEDs acting on sodium channels, e.g. carbamazepine and phenytoin, the neuroprotective effects have been proven at the same time [23].

The research aiming at the understanding of molecular mechanism of action of TP-315 also included human α7 and human α4β2 nicotinic acetylcholine receptors (nAChRs). Although they do not belong to the main molecular targets of AEDs, the literature reports suggest that these receptors may play a significant role in pathophysiology of many neurological diseases, including epilepsy [24]. Significantly altered activity of nAChRs was observed in some types of epilepsy. This mainly concerns juvenile myoclonic epilepsy and autosomal dominant nocturnal frontal lobe epilepsy – ADNFLE [24]. Moreover, it has been found out that AEDs affect the function of nAChRs and that some of nAChRs antagonists show strong anticonvulsant effects in animal models of epilepsy [25]. For example, amino-alkyl-cyclohexanes efficiently protected mice and rats from seizures induced by electric shock (MES test) or nicotine. Median effective doses (ED50) for these derivatives reached 3.6 mg/kg in the MES test [26], and 2.46 mg/kg [25] in the nicotine-induced seizure model of epilepsy.

During the present research, the affinity of TP-315 towards some of the nAChRs was tested using radioligand binding technique. During the experiments, the level of displacement of [3H]epibatidine from its complexes with α4β2 and α7 receptors was measured. The mentioned receptors constitute the two main types of nicotinic acetylcholine receptors in the brain [27]. They differ in their sensibility to nicotine. Nicotine’s affinity for human α4β2 nAChRs is nearly 1000 times higher than that for α7 receptor. It is also thought that nicotine-induced seizures are mediated mainly by α7 nAChRs [28]. In the course of our experiments it has been found that TP-315 does not possess affinity to epibatidine-binding sites on human α4β2 and α7 nAChRs.

An important stage of the pre-clinical trials, the drug-candidates are subject to, is to check the effect of those compounds on human cells and tissues. Therefore, it is recommended that, at the stage of cytotoxicity testing, there are applied methods allowing determination of the tested compound’s effect on different phases of the cell cycle [29]. First of all, such methods measure the mitochondrial activity of cells, and therefore it is an early indicator of cellular toxicity. In turn, ToxiLight assay, whose principle consists in the measurement of adenylate kinase released from damaged cell membranes, is an indicator of cellular necrosis. Based on the results obtained from both PrestoBlue and ToxiLight assays it has been demonstrated that TP-315 is characterized by low toxicity for human hepatic HepG2 cells. While assessing the possible toxicity of drug-candidates, one should also observe the restrictions associated with in vitro methods. First of all, such methods measure the effect of chemical compounds on isolated cells, and therefore no interactions occurring in a living organism between different tissues and organs are taken into account. Therefore, it is worth mentioning...
that TP-315 was also tested in in-vivo model of neurotoxicity, i.e. in the chimney test [4]. The median toxic dose (TD50) for TP-315 administered 15min before the test was 462.9 ± 20.0 mg/kg, and the respective protective index (PI = TD50/ED50) value amounted to 9.7.

Conclusions

The presented study reports that the anticonvulsant activity of 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (TP-315) is at least the effect of its influence on the voltage-gated sodium channels (VGSCs). At the same time there has been excluded the possibility of interactions of TP-315 with orthosteric and allosteric binding sites on GABA_A receptors. Moreover, it has been found that TP-315 does not interact with epibatidine-binding sites on human α4β2 and α7 nAChRs. We also found that TP-315 affected the viability of human hepatic HepG2 cells to a slight degree only. The results obtained enabled to identify the plausible mechanism of action for TP-315. Moreover, the potent anticonvulsant activity together with low (neuro)toxicity, justify the further preclinical and hopefully clinical development of TP-315 as potential candidate for new antiepileptic drug.

Acknowledgements

The research was supported by grant from the National Science Centre, Poland (Sonata funding, UMO-2013/11/D/NZ7/01170).

The authors thank to Novartis for kind donation of HEK-293 and SH-SY5Y cells transfected with genes encoding ha4β2 and ha7 nAChRs, respectively.

Competing Interests

The authors have declared that no competing interest exists.

References

[1] Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsy 2005; 46: 858-877.
[2] Löscher W. How to explain multidrug resistance in epilepsy? Epilepsy Curr 2005; 5: 107-112.
[3] Pernica E, Meador KJ. Adverse effects of anti epileptic drugs. Acta Neurol Scand Suppl 2005; 181: 30-35.
[4] Plech T, Luszczki JJ, Wójcik M, Paneth A, Siwek A, Kolaczkowski M, Zolnierek M, Nowak G. Studies on the anticonvulsant activity of 4-alkyl-1,2,4-triazole-3-thiones and their effect on gabaeergic system. Eur J Med Chem 2014; 86: 690-699.
[5] Plech T, Luszczki JJ, Wójcik M, Paneth A, Siwek A, Kolaczkowski M, Zolnierek M, Nowak G. Studies on the anticonvulsant activity and influence on GABA-ergic neurotransmission of 1,2,4-triazole-3-thione based compounds. Molecules 2014; 19: 11729-11592.
[6] Sigel E, Steinmann ME. Structure, function, and modulation of GABA_A receptors. J Biol Chem 2012; 287: 40224-40231.
[7] Löscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant activity. II. Maximal electroshock seizure models. Epilepsy Res 1991; 8: 79-94.
[8] Rogawski MA, Tofighy A, White BS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res 2015; 118: 209-225.
[9] Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007; 4: 18-61.
[10] Taylor CP, Meldrum BS. Nar channels as targets for neuroprotective drugs. Trends Pharmacol Sci 1995; 16: 309-316.
[11] Waxman SG. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis - current status. Nature Clin Pract Neurol 2008; 4: 159-169.
[12] Cunha AO, Mortari MR, Liberato JL, dos Santos WF. Neuroprotective effects of diazepam, carbamazepine, phenytoin and ketamine after pilocarpine-induced status epilepticus. Basic Clin Pharmacol Toxicol 2009; 104: 470-477.
[13] Chasseur M, Hadjipour-Niktarash A. Pathologic role of neuronal nicotinic acetylcholine receptors in epileptic disorders: implication for pharmacological interventions. Rev Neuroscience 2015; 26: 199-223.
[14] Löscher W, Potschka H, Wlaź P, Danysz W, Parsons CG. Are neuronal nicotinic receptors a target for antiepileptic drug development? Studies in different seizure models in mice and rats. Eur J Pharmacol 2003; 466: 99-111.
[15] Parsons CG, Dansyz W, Bartmann A, Spielmann P, Frankiewicz T, Hesselink M, Eiblacher B, Quack G. Amino-alkyl-cyclohexanes are novel competitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 1999; 38: 85-108.
[16] Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 1999; 22: 555-561.
[17] Dangui MF, Glassw W, Dukat M, Martin BR. Pharmacological characterization of nicotine-induced seizures in mice. J Pharmacol Exp Ther 1999; 291: 1284-1291.
[18] Miret S, de Groene EM, Klaffke W. Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2. J Biomol Screen 2006; 11: 184-193.